TapImmune Provides Third Quarter 2017 Corporate and Clinical Update

Conference Call and Live Audio Webcast Scheduled for Today, November 15, 2017, at 4:30 p.m. ET

[/vc_column_text][vc_column_text]Recent Corporate and Clinical Developments:

  • Appointed Peter Hoang as President and CEO
  • Completed enrollment in ongoing Phase 2 dosing study of TPIV200 for treating triple-negative breast cancer (TNBC)
  • Began enrolling patients into Phase 2 platinum-sensitive ovarian cancer study under an amended protocol that allows women in their first remission to receive TPIV200 vaccination
  • Continued to advance clinical development pipeline in multiple Phase 2 studies in ovarian and breast cancer

Upcoming Anticipated Milestones:

  • 2017: Mayo Clinic expected to commence dosing in 280-patient, grant-funded Phase 2 study of TPIV200 in women with advanced TNBC
  • 2017: Publish long-term immune response and progression-free survival data from completed Phase 1 clinical study of TPIV200
  • 2017: Complete FDA filings required to initiate studies with TPIV 110 for treating HER2/neu+ breast cancer
  • 1H 2018: Report interim immune response data from ongoing Phase 2 TNBC
  • 1H 2018: Report interim results from ongoing Phase 2 study of TPIV200 in combination with AstraZeneca’s durvalumab in patients with platinum-resistant ovarian cancer
  • 1H 2018: Mayo Clinic to initiate Phase 1b/2a study of TPIV100 in women with HER2/neu+ ductal carcinoma in situ (DCIS) breast cancer

JACKSONVILLE, FLORIDA – November 15, 2017 – TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today provided its business update for the third quarter 2017. A public conference call and live audio webcast is scheduled for today at 4:30 p.m. ET.

“TapImmune continued to advance its clinical and preclinical programs in the third quarter, which I believe positions us very well to achieve a number of important milestones in 2017 and beyond,” said Peter Hoang, President and CEO of TapImmune. “I believe TapImmune is well positioned to advance immuno-oncology with its broadly effective cancer vaccine candidates and proprietary technologies in the indications and treatment settings we are targeting.  Having joined the company in late September, I was drawn to TapImmune because I see an opportunity to lead our industry, in translating the promise of cancer immunotherapy into potentially life-changing therapeutic outcomes.

“As we continue to advance our deep clinical pipeline, I am determined to drive TapImmune to its full potential. Our primary objective is to continue executing on our active Phase 2 trials as efficiently as possible.  We and our clinical partners also expect to launch additional clinical studies for each of our novel cancer vaccine candidates in order to further highlight their potential and generate even more value for the company. I believe that driving clinical execution should lead to several significant catalysts for the company and its shareholders over the coming quarters and years. I expect to drive efficiencies from an operational, regulatory and commercial standpoint, so that we achieve every milestone we set for the company.  In parallel, my goal is to drive enhanced appreciation and support for TapImmune by the investor community.  Finally, I intend to pursue opportunities to bolster our pipeline through strategic corporate and business development initiatives, in an effort to further expand the market opportunity for TapImmune.”

Current Clinical Studies:

 TPIV200: Lead T-cell vaccine targeting folate receptor alpha

  • Multi-center Phase 2 dosing study in triple-negative breast cancer

The randomized study is designed to determine the optimal vaccine dose and regimen that may maximize the anti-tumor immune response in maintenance-phase patients, who have completed standard surgery and chemotherapy/radiation. TapImmune reached its enrollment target ahead of schedule, and currently expects to report interim immune response data in the first half of 2018.

  • FDA Fast Tracked Phase 2 maintenance therapy study in platinum-sensitive ovarian cancer

TapImmune is currently enrolling women who have completed initial therapy with a platinum regimen and are in first remission. Enrollment remains on track with projections and the company plans to conduct a blinded interim safety and futility analysis once the data from the first half of enrollment is achieved and responses mature, which is currently expected in early 2019.  This program benefits from FDA Fast Track and Orphan Drug designation.

  • Memorial Sloan Kettering-sponsored Phase 2 combination study with AstraZeneca’s durvalumab in platinum-resistant ovarian cancer

Data from the first 27 patients enrolled in the study are currently being analyzed by the study’s clinical investigators at MSKCC.  TapImmune anticipates reporting the results based on these 27 patients in the first half of 2018. If the safety profile remains favorable and there are sufficient signs of tumor response, patient enrollment may resume and the study can be completed as designed.

Planned Clinical Studies:


  • Mayo Clinic is expected to commence dosing in a Phase 2 study designed to evaluate the efficacy of TPIV200 in prolonging disease-free survival in women with advanced triple-negative breast cancer. This 280-patient study is planned to commence dosing in the fourth quarter 2017, and is completely funded by a $13.3 million grant from the U.S. Department of Defense.

TPIV100/110 T-cell vaccine targeting HER2/neu:

  • TapImmune plans to complete FDA filings required to initiate a Phase 1b/2a clinical study with TPIV110, its five-peptide vaccine candidate for treating women with HER2/neu+ breast cancer.
  • Mayo Clinic is expected to initiate a Phase 1b/2a study of TPIV100 in women with an early form of breast cancer called ductal carcinoma in situ (DCIS).  This study is also fully funded by a grant from the U.S. Dept. of Defense. If successful, TapImmune’s HER2/neu-targeted vaccine may complement standard surgery and chemotherapy.

Conference Call and Webcast Information:

The company will host a conference call and live audio webcast today, November 15, 2017, at 4:30 p.m. ET. Interested participants and investors may access the conference call by dialing either:

  • (855) 238-2333 (U.S.)
  • (412) 317-5215 (International)

An audio webcast will be accessible via the New and Events section of the TapImmune website https://www.markertherapeutics.com/events/. An archive of the webcast and presentation will remain available for 90 days beginning at approximately 6:30 p.m. ET, on November 15, 2017.[/vc_column_text][vc_empty_space height=”8px”][vc_column_text][pr-disclaimer][/vc_column_text][vc_empty_space height=”8px”][vc_column_text]




Three Months Ended   Nine Months Ended
September 30,   September 30,
2017 2016   2017 2016
Operating expenses:
Research and development  $1,623,302  $1,109,332  $3,815,119 $3,343,248
General and administrative  2,549,272  1,612,305  5,167,582  3,557,701
Total operating expenses  4,172,574  2,721,637  8,982,701  6,900,949
Loss from operations  (4,172,574)  (2,721,637)  (8,982,701)  (6,900,949)
Other income (expense):
Change in fair value of warrant liabilities  4,000  684,000  8,500  5,925,000
Debt extinguishment gain  –  –  492,365  –
Grant income  183,064  –  183,064  231,200
Loss on debt settlement agreements  –  (65,325)  –  (135,640)
Other income  –  –  –  1,828
Net loss $(3,985,510) $(2,102,962) $(8,298,772)  $(878,561)
Basic net loss per share  $(0.39)  $(0.29)  $(0.91)  $(0.14)
Diluted net loss per share  $(0.39)  $(0.29)  $(0.91)  $(0.54)
Weighted average number of common shares outstanding, basic  10,219,138  7,281,000  9,081,678  6,370,000
Weighted average number of common shares outstanding, diluted  10,219,138  7,281,000  9,081,678  6,935,000




September 30, December 31,
2017 2016
Current assets:
Cash  $7,607,735  $7,851,243
Prepaid expenses and deposits  96,530  70,149
Total current assets  7,704,265  7,921,392
Total assets  $7,704,265  $7,921,392
Current liabilities:
Accounts payable and accrued liabilities  $1,757,062  $1,224,940
Research agreement obligations  –  492,365
Warrant liability  6,000  14,500
Promissory note  5,000  5,000
Total current liabilities  1,768,062  1,736,805
Total liabilities  1,768,062  1,736,805
Stockholders’ equity:
Preferred stock – $0.001 par value, 5 million shares authorized at September 30, 2017 and December 31, 2016, respectively
Series A, $0.001 par value, 1.25 million shares designated, 0 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively  –  –
Series B, $0.001 par value, 1.5 million shares designated, 0 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively  –  –
Common stock, $0.001 par value, 41.7 million shares authorized, 10.5 million and 8.4 million shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively  10,539  8,421
Additional paid-in capital  160,662,286  151,991,974
Accumulated deficit  (154,736,622)  (145,815,808)
Total stockholders’ equity  5,936,203  6,184,587
Total liabilities and stockholders’ equity  $7,704,265  $7,921,392




Nine Months Ended
September 30,
2017 2016
Cash Flows from Operating Activities:
Net loss  $(8,298,772)  $(878,561)
Reconciliation of net loss to net cash used in operating activities:
Changes in fair value of warrant liabilities  (8,500)  (5,925,000)
Shares issued in debt settlement agreements  –  70,315
Stock-based compensation  2,332,915  1,309,109
Debt extinguishment gain  (492,365)  –
Changes in operating assets and liabilities:
Prepaid expenses and deposits  (26,381)  (42,849)
Accounts payable and accrued expenses  532,122  710,720
Net cash used in operating activities  (5,960,981)  (4,756,266)
Cash Flows from Financing Activities:
Proceeds from issuance of common stock and warrants in private placement, net of offering costs  5,408,343  2,331,126
Proceeds from exercise of stock warrants, net of offering costs  619,623  5,483,349
Repayment of promissory note  –  (25,000)
Repayment of promissory note – related party  –  (23,000)
Repurchase of common stock to pay for employee withholding taxes  (310,493)  –
Net cash provided by financing activities  5,717,473  7,766,475
Net (decrease) increase in cash  (243,508)  3,010,209
Cash at beginning of period  7,851,243  6,576,564
Cash at end of period  $   7,607,735  $       9,586,773